Additionally, two prognostic molecular biomarkers are included in GBM typing, namely isocitrate dehydrogenase (IDH) mutations (typically absent in primary GBM [5]) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation [6]. This evidence concerns the gene IDH1 and glioblastoma.